Best-of-ASCO Germany 2011 – Aktuelles zu GI-Tumoren, zum NSCLC und zur Supportivtherapie: Chicago meets Frankfurt

Erstmals fand dieses Jahr in Deutschland die von der Amerikanischen Gesellschaft für Klinische Onkologie (ASCO) lizenzierte Post-ASCO-Nachlese „Best-of-ASCO Germany“ statt. Auf der Veranstaltung, die vom Arbeitskreis Klinischer Studien e.V. (AKS) und der Deutschen Krebsgesellschaft (DKG) in Kooperation mit den Fachgesellschaften durchgeführt wurde, kommentierten renommierte Experten aus Deutschland interessenunabhängig wegweisende Studiendaten von der diesjährigen 47. ASCO-Jahrestagung, darunter auch Daten zur Supportivtherapie.

• Literatur

• 1 Agnelli G. et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. J Clin Oncol. 2011 29. (suppl; abstr LBA9014).
• 2 Bang Y. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial. J Clin Oncol. 2011 29. (suppl; abstr LBA4002).
• 3 Cohen L. et al. Effect of yoga on QOL, cortisol rhythym, and HRV for women with breast cancer undergoing radiotherapy. J Clin Oncol. 2011 29. (suppl; abstr 9009).
• 4 Guo Y. et al. A randomized, double-blinded, placebo-controlled trial of oral alpha lipoic acid to prevent platinum-induced polyneuropathy. J Clin Oncol. 2011 29. (suppl; abstr 9010).
• 5 Hofheinz R. et al. Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial. J Clin Oncol. 2011 29. (suppl; abstr 3504).
• 6 Marrero JA. et al. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. J Clin Oncol. 2011 29. (suppl; abstr 4001).
• 7 Park SH. et al. A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). J Clin Oncol. 29. 2011 (suppl; abstr 4004). J Clin Oncol 2011; 29 (suppl; abstr 3504)
• 8 Paz-Ares LG. et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2011 29. (suppl; abstr CRA7510).
• 9 Pressiani T. et al. Pase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment. J Clin Oncol. 2011 29. (suppl; abstr 4115).
• 10 Rödel C. et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol. 2011 29. (suppl; abstr LBA3505).
• 11 Rosell R. et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol. 2011 29. (suppl; abstr 7503).
• 12 Roth MS. et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol. 2011 29. (suppl; abstr 3503).
• 13 Scagliotti G. et al. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2011 29. (suppl; abstr LBA7512).
• 14 Schneider BP. et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. J Clin Oncol. 2011 29. (suppl; abstr 1000).
• 15 Yothers GA. et al. The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. J Clin Oncol. 2011 29. (suppl; abstr 3507).
• 16 Zhang L. et el. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). J Clin Oncol. 2011 29. (suppl; abstr LBA7511).